Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.
We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.
We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.
We make our efforts to offer customer innovative, customized, high-quality service.
Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.
SCH900776 is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with IC50 of 3 nM, and has much greater selectivity against Chk2 (IC50=1500 nM) and cyclin-dependent kinase CDK2 (IC50=160 nM). IC50 & Target: IC50: 3 nM (Chk1), 160 nM (CDK2), 1500 nM (Chk2) In Vitro: SCH900776 (300 nM) is effective effective at inhibiting phosphorylation at ser296-Chk1. SCH900776 (1 μM) causes a 30-fold decrease in the IC50 for hydroxyurea in MDA-MB-231 cells. The Kd of SCH 900776 for the CHK1 kinase domain is 2 nM. SCH 900776 exhibits an approximate EC50 of 60 nM. SCH 900776 induces dose-dependent suppression of CHK1 pS296 and concomitant accumulation of phospho-RPA signal in U2OS cells. In Vivo: SCH 900776 (4 mg/kg, p.o.) induces the γ-H2AX biomarker; SCH 900776 (16 and 32 mg/kg) induces incremental improvements in tumor response. Escalation of SCH 900776 dose to 20 and 50 mg/kg in combination with gemcitabine leads to improvements in TTP 10x in the A2780 xenograft systems